Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments

The Stroke Therapy Academic Industry Roundtable (STAIR) provided initial (in 1999) and updated (in 2009) recommendations with the goal of improving preclinical stroke therapy assessment and to increase the translational potential of experimental stroke treatments. It is important for preclinical str...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael P. Kahle, Gregory J. Bix
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Stroke Research and Treatment
Online Access:http://dx.doi.org/10.1155/2012/374098
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832546762344103936
author Michael P. Kahle
Gregory J. Bix
author_facet Michael P. Kahle
Gregory J. Bix
author_sort Michael P. Kahle
collection DOAJ
description The Stroke Therapy Academic Industry Roundtable (STAIR) provided initial (in 1999) and updated (in 2009) recommendations with the goal of improving preclinical stroke therapy assessment and to increase the translational potential of experimental stroke treatments. It is important for preclinical stroke researchers to frequently consider and revisit these concepts, especially since promising experimental stroke treatments continue to fail in human clinical trials. Therefore, this paper will focus on considerations for several key aspects of preclinical stroke studies including the selection and execution of the animal stroke model, drug/experimental treatment administration, and outcome measures to improve experimental validity and translation potential. Specific points of interest discussed include the incorporation of human comorbid conditions and drugs, the benefits of defining a proposed mechanism of action, replication of results using multiple methods, using clinically relevant routes of administration and treatment time windows, and performing and reporting good experimental methods to reduce bias such as, as suggested by the updated STAIR recommendations, sample size calculations, randomization, allocation concealment, blinding, and appropriate inclusion/exclusion criteria. It is our hope that reviewing and revisiting these considerations will benefit researchers in their investigations of stroke therapies and increase the likelihood of translational success in the battle against stroke.
format Article
id doaj-art-bfba87cb4bd045f59178102e1bcdfcb0
institution Kabale University
issn 2090-8105
2042-0056
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Stroke Research and Treatment
spelling doaj-art-bfba87cb4bd045f59178102e1bcdfcb02025-02-03T06:47:24ZengWileyStroke Research and Treatment2090-81052042-00562012-01-01201210.1155/2012/374098374098Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke TreatmentsMichael P. Kahle0Gregory J. Bix1Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M Health Science Center, Bryan, TX 77807, USASanders-Brown Center on Aging and Department of Anatomy and Neurobiology, University of Kentucky, 430 Sanders Brown Building 800 S. Limestone Street, Lexington, KY 40536, USAThe Stroke Therapy Academic Industry Roundtable (STAIR) provided initial (in 1999) and updated (in 2009) recommendations with the goal of improving preclinical stroke therapy assessment and to increase the translational potential of experimental stroke treatments. It is important for preclinical stroke researchers to frequently consider and revisit these concepts, especially since promising experimental stroke treatments continue to fail in human clinical trials. Therefore, this paper will focus on considerations for several key aspects of preclinical stroke studies including the selection and execution of the animal stroke model, drug/experimental treatment administration, and outcome measures to improve experimental validity and translation potential. Specific points of interest discussed include the incorporation of human comorbid conditions and drugs, the benefits of defining a proposed mechanism of action, replication of results using multiple methods, using clinically relevant routes of administration and treatment time windows, and performing and reporting good experimental methods to reduce bias such as, as suggested by the updated STAIR recommendations, sample size calculations, randomization, allocation concealment, blinding, and appropriate inclusion/exclusion criteria. It is our hope that reviewing and revisiting these considerations will benefit researchers in their investigations of stroke therapies and increase the likelihood of translational success in the battle against stroke.http://dx.doi.org/10.1155/2012/374098
spellingShingle Michael P. Kahle
Gregory J. Bix
Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments
Stroke Research and Treatment
title Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments
title_full Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments
title_fullStr Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments
title_full_unstemmed Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments
title_short Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments
title_sort successfully climbing the stairs surmounting failed translation of experimental ischemic stroke treatments
url http://dx.doi.org/10.1155/2012/374098
work_keys_str_mv AT michaelpkahle successfullyclimbingthestairssurmountingfailedtranslationofexperimentalischemicstroketreatments
AT gregoryjbix successfullyclimbingthestairssurmountingfailedtranslationofexperimentalischemicstroketreatments